Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tissue firms partner

This article was originally published in The Gray Sheet

Executive Summary

Regeneration Technologies and Tutogen Medical enter a mutual sourcing agreement Nov. 6 whereby RTI gains access to soft tissue used in sports medicine surgeries recovered by Tutogen's recovery partners, and Tutogen obtains the rights to dermis, fascia and pericardium recovered by RTI Donor Services agencies. The partnership enables maximum use of donated tissue, the firms say...

You may also be interested in...



Regeneration/Tutogen Merger Creates Broad Biologic Implant Portfolio

Regeneration Technologies Inc. will maintain both the BioCleanse and Tutoplast tissue sterilization processes for making biologic implants following its acquisition of Tutogen in a $263 million stock-swap deal, announced Nov. 13

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel